+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder



Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder



Journal of Clinical Psychiatry 78(8): E947-E956



Many studies have investigated cerebrospinal fluid (CSF) monoamine metabolite levels in depressive disorders. However, their clinical significance is still unclear. We tried to determine whether CSF monoamine metabolite levels could be a state-dependent marker for major depressive disorder (MDD) based on analyses stratified by clinical variables in a relatively large sample. Subjects were 75 patients with MDD according to DSM-IV criteria and 87 healthy controls, matched for age, sex, and ethnicity (Japanese). They were recruited between May 2010 and November 2013. We measured homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in CSF samples by high-performance liquid chromatography. We analyzed the relationships of the metabolite levels with age, sex, diagnosis, psychotropic medication use, and depression severity. There was a weak positive correlation between age and 5-HIAA levels in controls (ρ = 0.26, P < .016) and a similar trend in patients, while sex was unrelated to any metabolite. All monoamine metabolites in moderately to severely depressed patients (17-item Hamilton Depression Rating Scale score > 12) were significantly lower than those in controls (P < .0005 for all 3 metabolites). We found that antidepressants decreased the levels of 5-HIAA (ρ = -0.39, P < .001) and MHPG (ρ = -0.49, P < .0001) and that antipsychotics increased levels of HVA (ρ = 0.24, P < .05). There was a strong correlation between HVA and 5-HIAA levels (controls: ρ = 0.79, P = .000001; MDD: ρ = 0.66, P = .000001). HVA levels (ρ = -0.43, P < .001) and 5-HIAA levels (ρ = -0.23, P < .05), but not MHPG levels (ρ = -0.18, P > .1), were related to depression severity. CSF 5-HIAA and HVA levels could be state-dependent markers in MDD patients. Since 5-HIAA levels greatly decrease with the use of antidepressants, HVA levels might be more useful in the clinical setting.

(PDF emailed within 1 workday: $29.90)

Accession: 060190133

Download citation: RISBibTeXText

PMID: 28749090


Related references

Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 76: 12-18, 2017

Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence. Journal of Psychiatric Research 105: 137-146, 2018

No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. Psychiatry Research 263: 30-34, 2018

No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. Psychiatry Research 263: 30-34, 2018

A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Bipolar Disorders 8(5 Pt 2): 543-550, 2006

Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatrica Scandinavica 83(2): 125-133, 1991

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder. Psychiatry Research 254: 244-250, 2017

Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochemical and Biophysical Research Communications 497(2): 683-688, 2018

Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. Journal of Psychiatric Research 113: 190-198, 2019

Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder. International Journal of Neuropsychopharmacology 22(4): 261-269, 2019

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research 47(3): 401-406, 2014

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 17(9): 573-579, 2007

Cerebrospinal fluid monoamine and monoamine metabolite levels and the dexamethasone suppression test in depression. Archives of General Psychiatry 43(4): 356-360, 1986

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder. World Journal of Biological Psychiatry 16(2): 106-113, 2015

Increased cerebrospinal fluid fibrinogen levels in major depressive disorder replicated in a larger sample set. European Neuropsychopharmacology 26: S403-S404, 2016